Catch up on the latest breakthroughs in bladder cancer management. In this episode of the BackTable Urology Podcast, Dr. Bogdana Schmidt (University of Utah) speaks with Dr. Andrea Apolo, a medical oncologist at the National Cancer Institute, about recent advancements in bladder cancer treatment presented at the 2024 European Society of Medical Oncology (ESMO) Congress.

---

SYNPOSIS

They review pivotal trials like the NIAGARA and AMBASSADOR studies, the TAR-200 drug delivery system, the use of bladder-sparing treatment, and the role of ctDNA as a biomarker. Further, they detail the effectiveness of systemic therapies such as gemcitabine and pembrolizumab, the implications of perioperative immunotherapy, and the future role of antibody-drug conjugates. The conversation highlights the trend towards less invasive approaches while improving survival rates from bladder cancer.

---

TIMESTAMPS

00:00 - Introduction

03:49 - NIAGARA Trial

09:10 - Challenges in Bladder Cancer Treatment

18:56 - AMBASSADOR Trial

25:30 - Adjuvant Immunotherapy

29:30 - Exploring Biomarkers and ctDNA

36:34 - Surgery and Less Invasive Therapies

46:31 - Future Directions in Bladder Cancer Treatment

---

RESOURCES

ESMO

https://www.esmo.org/